...
首页> 外文期刊>Circulation. Genomic and precision medicine. >ET (Endothelin)-I and IschemicHeart Disease A Mendelian Randomization Study
【24h】

ET (Endothelin)-I and IschemicHeart Disease A Mendelian Randomization Study

机译:ET(内皮素)我和IschemicHeart疾病孟德尔随机化研究

获取原文
获取原文并翻译 | 示例
           

摘要

ET (endothelin)-l is a vasoconstrictive peptide. ET receptor antagonists are used to treat pulmonary hypertension. Whether ET-1 is a target of intervention in cardiovascular disease or a symptom of vascular damage is unclear. A genetic variant promoting ET-1 expression was recently found positively associated with ischemic heart disease (IHD).1 Here, we used separate sample Mendelian randomization (MR), that is, instrumental variable analysis with genetic instruments, to assess whether ET-1 is associated with IHD and for completeness with myocardial infarction (MI) and some of their major risk factors.
机译:ET(内皮素)- l vasoconstrictive肽。ET受体拮抗剂用于治疗肺动脉高压。心血管疾病或干预血管损伤的症状尚不清楚。最近变异促进ET-1表达式发现与缺血性心脏呈正相关疾病(IHD)。1孟德尔随机化(先生),工具变量和遗传分析工具,以评估ET-1是否相关与心肌进行胆道和完整性梗死和他们的一些主要风险的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号